Details of the Drug Metabolized by Drug-Metabolizing Enzyme (DME)

General Information of Drug (ID: DR5515)
Drug Name
Olsalazine
Synonyms Azodisal; Dipentum; Olsalazine sodium; Di-mesalazine
Indication Ulcerative colitis [ICD11: DD71] Approved [1]
Structure
3D MOL 2D MOL
Pharmaceutical Properties Molecular Weight 302.24 Topological Polar Surface Area 140
Heavy Atom Count 22 Rotatable Bond Count 4
Hydrogen Bond Donor Count 4 Hydrogen Bond Acceptor Count 8
Cross-matching ID
PubChem CID
22419
ChEBI ID
CHEBI:7770
CAS Number
15722-48-2
TTD Drug ID
D00KRE
Formula
C14H10N2O6
Canonical SMILES
C1=CC(=C(C=C1N=NC2=CC(=C(C=C2)O)C(=O)O)C(=O)O)O
InChI
InChI=1S/C14H10N2O6/c17-11-3-1-7(5-9(11)13(19)20)15-16-8-2-4-12(18)10(6-8)14(21)22/h1-6,17-18H,(H,19,20)(H,21,22)
InChIKey
QQBDLJCYGRGAKP-UHFFFAOYSA-N
The Metabolic Roadmap of This Drug
The Full List of Drug Metabolites (DM) of This Drug
DM Name DM ID PubChem ID Reaction DM Level REF
Mesalazine DM000380
4075
Unclear - Unclear 1 [2]
N-acetyl?mesalazine DM015044
65512
Unclear - Unclear 2 [2]
The Full List of Metabolic Reaction (MR) of This Drug
MR ID Reactant Product MR Type DME REF
MR010719 Olsalazine Mesalazine Unclear - Unclear Unclear [2]
MR010720 Mesalazine Acetyl-mesalazine Unclear - Unclear Unclear [2]
References
1 ClinicalTrials.gov (NCT00004288) Phase II Pilot Study of Olsalazine for Ankylosing Spondylitis. U.S. National Institutes of Health.
2 Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease. Drugs. 1991 Apr;41(4):647-64.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.